Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“NovoSeven has been a lifesaving treatment for many people with Glanzmann Thrombasthenia, but I want those in the community to know that it’s important to remember that no medication is perfect.
Like all newer drugs, NovoSeven passed clinical trials, but long-term effects, rare complications, and real-world outcomes still take time to understand fully.
Approval does not mean a treatment is 100% effective or risk-free.
I hope that when adverse events or unexpected outcomes occur, Novo Nordisk thoroughly investigates them and shares those findings publicly. The GT community benefits from transparency, whether the results are positive or negative.
I always say:
Read the fine print, no matter how long or small; ask questions; and understand both the benefits and risks of any treatment you use.
The more we learn, the better care future GT patients will receive.”
Other posts featuring Peter Zdziarski on Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026